Serono Completes Patient Enrollment in Rebif(R) Versus Copaxone(R) Comparative Clinical Trial

Serono (virt-x: SEO and NYSE: SRA) announced today that patient enrollment has been completed in a multi-national Rebif(R) (interferon beta-1a) versus Copaxone(R) (glatiramer acetate) comparative clinical trial. This two-year trial is designed to compare the efficacy of the two therapies in patients with relapsing remitting multiple sclerosis (RRMS), who were previously untreated with disease modifying therapies.

More here.

January 5, 2005 in copaxone, rebif, research, worth following... | Permalink | Comments (0)

Brain-protecting Protein Boosted by Multiple Sclerosis Drug

A drug used to treat multiple sclerosis has been found to stimulate immune system cells to produce a brain-protecting protein.

Researchers at the University of Maryland School of Medicine have shown that the drug, Copaxone, stimulates T cells to produce a protein called brain-derived neurotrophic factor.

Read more here.

December 3, 2003 in copaxone, research | Permalink | Comments (0)

Clinical Effects of COPAXONE(R) or Interferon Therapy Compared to Untreated RRMS Patients

The percentages of relapse-free patients in each group were: COPAXONE -- 83 percent; Avonex -- 65 percent; Rebif -- 60 percent; Betaseron -- 60 percent; no treatment -- 37 percent.

Adriana Carra, M.D., Department of Neurology, Hospital Britanico de Buenos Aires, Argentina, spoke about the results. "It is clear that immunomodulatory therapy is beneficial in the long-term treatment of relapsing-remitting patients compared to no treatment. Our data are similar to those observed in other studies published or presented."

Read it here.

November 5, 2003 in avonex, betaseron, copaxone, interferon-beta, rebif, research | Permalink | Comments (0)

Teva Reports Q3 Net Income of $157 Million, Up 63%

"This has been yet another successful quarter, with record sales and net income, resulting from strong performance in our major markets and with our major products including Copaxone", said Israel Makov, Teva's President and CEO.

Just doing our part for the economy...

Read it here

November 2, 2003 in copaxone, economy, follow the money..., stocks | Permalink | Comments (0)

Teva to Acquire Sicor for $3.25 Billion

"Teva, which makes generic drugs and the multiple sclerosis medicine Copaxone, said the deal is designed to gain Sicor's expertise in generic injectable drugs and its capabilities in duplicating the wave of biotechnology drugs that are coming on the market once those drugs lose patent protection."

Read it here.

November 1, 2003 in copaxone, economy, follow the money..., stocks | Permalink | Comments (0)